Adherence to disease modifying drugs of patients with multiple sclerosis (ADAPIMS)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/16992
• EU PAS number:
  EUPAS3330
• Study ID:
  16992
• Official title and acronym:
  Adherence to disease modifying drugs of patients with multiple sclerosis (ADAPIMS)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  Objective is to evaluate the adherence of patients to disease modifying drugs
• Study status:
  Finalised

Research institutions and networks

Institutions

Deutsches Arzneiprüfungsinstitut e.V. (DAPI)

Study timelines

Date when funding contract was signed

Planned: 18/07/2012

Actual: 03/09/2012

Study start date

Planned: 01/01/2013

Actual: 06/05/2013

Data analysis start date

Planned: 01/05/2013

Actual: 01/04/2013

Date of final study report

Planned: 01/02/2016

Actual: 27/07/2015

Sources of funding

Other

More details on funding

DAPI, TU Dresden

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable